| ASCO | American Society of Clinical Oncology |
| ATF3 | Activating transcription factor 3 |
| BIPN | Bortezomib-induced peripheral neuropathy |
| CCL | CC chemokine ligand |
| CIPN | Chemotherapy-induced peripheral neuropathy |
| Cmax | Maximum blood concentration |
| CNS | Central nervous system |
| DRG | Dorsal root ganglia |
| ER | Endoplasmic reticulum |
| ERK | Extracellular signal-regulated protein kinase |
| FDA | the US Food and Drug Administration |
| GFAP | Glial fibrillary acidic protein |
| GLAST | Glutamate/aspartate transporter |
| IENF | Intraepidermal nerve fiber |
| IL | Interleukin |
| JNK | c-Jun N-terminal kinase |
| MAPK | Mitogen-activated protein kinase |
| mEPSCs | Miniature excitatory postsynaptic currents |
| NAD+ | Nicotinamide adenine dinucleotide |
| NF-κB | Nuclear factor kappa-light-chain-enhancer of activated B cells |
| NLRP3 | NOD-like receptor family pyrin domain containing 3 |
| PNS | Peripheral nervous system |
| PKC | Protein kinase C |
| ROS | Reactive oxygen species |
| SARM1 | Sterile alpha and toll/interleukin-1 receptor motif-containing 1 |
| S1P | Sphingosine-1-phosphate |
| S1PR | Sphingosine-1-phosphate receptor |
| STAT3 | Signal transducer and activator of transcription-3 |
| TNF-α | Tumor necrosis factor alpha |
| TRPA1 | Transient receptor potential ankyrin 1 |